Athena Heart [310] Site

: The trial established dronedarone as a rhythm-control therapy specifically aimed at reducing clinical complications rather than just maintaining sinus rhythm. 2. Dronedarone (Multaq) Usage Guide

: Contraindicated in patients with symptomatic heart failure or recent hospitalization for heart failure (NYHA Class IV or symptomatic Class II-III).

The official FDA label outlines critical safety measures based on ATHENA data: : ATHENA HEART [310]

: Dronedarone significantly reduced the primary composite endpoint of first cardiovascular hospitalization or death by 24% compared to a placebo.

: To determine if dronedarone could lower the risk of hospitalization due to cardiovascular events or death from any cause in patients with atrial fibrillation (AF) or atrial flutter (AFL). : The trial established dronedarone as a rhythm-control

: Do not use in patients who cannot or will not be converted to sinus rhythm.

The ATHENA trial was a landmark study that evaluated the efficacy of dronedarone in reducing cardiovascular hospitalizations or death. The official FDA label outlines critical safety measures

: Periodic testing is recommended due to reported cases of liver injury.